Compare Merck & Co., Inc. (MRK) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Simon Property Group Inc — how do they compare? Merck & Co., Inc. trades at $148.11 (market cap $366.28B), while Simon Property Group Inc trades at $204.58 (market cap $68.56B). The key difference: Merck & Co., Inc. is far larger — about 5.3× Simon Property Group Inc's market cap, and Simon Property Group Inc pays the higher dividend (4.2%). Which is the better fit depends on your goals.
| MRK | SPG | |
|---|---|---|
Market Cap | $366.28B | $68.56B |
Sector | Health | Real Estate |
52-Week High | $156.43 | $236.70 |
52-Week Low | $77.60 | $173.35 |
Enterprise Value | $413.04B | $97.00B |
Dividend Yield | 2.29% | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
SPG trades at $211.88, up 1.17% daily, with a bearish technical signal but strong fundamentals including a P/E of 14.95, robust net income margin of 66.57%, and recent Q2 2026 FFO beat. The company raised $800 million in senior notes (PRNewsWire, 2026-09-09) and launched Simon Media Network to monetize mall traffic (PRNewsWire, 2026-08-27), enhancing growth prospects despite a Q2 EPS miss.
Outlook is mixed: analyst consensus targets $231.82 with 42% buy ratings, but risks include high debt ($24.21B long-term) and bearish technicals. Opportunities lie in dividend yields and media initiatives, while headwinds involve retail real estate volatility and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
